LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

LLY

1,139.11

-2.1%↓

JNJ

240.65

+0.51%↑

ABBV

227.02

+0.2%↑

UNH

407.63

+0.41%↑

MRK

119.62

-2.28%↓

Search

Erasca Inc

Abierto

13.94 3.34

Resumen

Variación precio

24h

Actual

Mínimo

13.66

Máximo

14.57

Métricas clave

By Trading Economics

Ingresos

-154M

-183M

BPA

-0.6

Empleados

103

EBITDA

-5.3M

-37M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+49.89% upside

Dividendos

By Acuity

Próximas Ganancias

10 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

476M

3.7B

Apertura anterior

10.6

Cierre anterior

13.94

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jun 2026, 23:56 UTC

Event

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

11 jun 2026, 23:56 UTC

Correlated Moves
ETF Constituents
Macro News

iShares MSCI Brazil ETF trades higher after President Trump's cancellation of military strikes against Iran, boosting global investor confidence.

11 jun 2026, 23:56 UTC

News

Monster Beverage shares higher in after-market trading following Bernstein's initiation of coverage with a Market Perform rating. The stock has gained over four consecutive sessions.

11 jun 2026, 23:52 UTC

Michigan Consumer Sentiment Report for June 2026 Forecasts Continued Decline at 46.0 Amid Economic Pressures and Inflation Concerns

11 jun 2026, 23:52 UTC

Investors Await Key U.S. Building Permits Report Amid Cautious Market Sentiment Ahead of June 16 Release

11 jun 2026, 23:52 UTC

Macro Event
News
Correlated Moves

The Australian Dollar has gained against the Singapore Dollar, supported by a slight decline in consumer inflation expectations and recent geopolitical developments.

11 jun 2026, 23:51 UTC

News

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting concerns over inflation following a rise in the producer price index.

11 jun 2026, 23:51 UTC

Correlated Moves

Lam Research Corp is rising in after-market trading, supported by a broader market rally and strong momentum near the upper end of its one-month trading range.

11 jun 2026, 23:51 UTC

Correlated Moves

Costco Wholesale Corp shares are higher in after-market hours, supported by a rising Nasdaq 100 Index and positive sentiment in the consumer staples sector.

11 jun 2026, 23:51 UTC

Trip.com Group Ltd is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain this movement.

11 jun 2026, 23:51 UTC

ETF Constituents

Vanguard FTSE Europe ETF is trading lower in after-market hours, impacted by declines from holdings including HSBC and Diageo, despite a generally higher market.

11 jun 2026, 23:51 UTC

Marriott International Inc. shares declined in after-market hours following Thursday's close, with no specific news identified to explain the movement.

11 jun 2026, 23:51 UTC

PepsiCo Inc shares are higher in after-market hours, driven by a significant overall market trend. The stock remains below its 20-day moving average.

11 jun 2026, 23:51 UTC

Lululemon Athletica is trading lower in after-market hours, reflecting a decline since Thursday's close. It reached a session low earlier in the session.

11 jun 2026, 23:51 UTC

Correlated Moves
ETF Constituents
News
Social Media

SPDR S&P 500 ETF Trust rises in after-hours trading amid improved market sentiment and reduced geopolitical tensions in Iran, supported by strong performances from top holdings.

11 jun 2026, 23:51 UTC

Correlated Moves
ETF Constituents
News
Social Media

Invesco QQQ Trust Series I rises after hours, supported by a Nasdaq 100 rally driven by technology stocks and easing inflation concerns.

11 jun 2026, 23:51 UTC

ETF Constituents
Correlated Moves
Macro News

Global X Copper Miners ETF declines in after-market trading as top holdings BHP and Southern Copper Corporation show slight decreases.

11 jun 2026, 23:51 UTC

Correlated Moves

Microchip Technology Inc is rising in after-market trading, reflecting broader market trends amid the European Central Bank's recent interest rate hike.

11 jun 2026, 23:51 UTC

Social Media
Correlated Moves

Micron Technology is trading higher in after-market hours, supported by positive market trends and favorable social media sentiment ahead of upcoming earnings.

11 jun 2026, 23:51 UTC

Correlated Moves

The Nasdaq 100 Index is higher today, continuing its upward trend. Initial jobless claims rose unexpectedly, but this has not impacted the index's momentum.

11 jun 2026, 23:51 UTC

News

The United States Oil Fund LP is higher in after-market trading amid reports of explosions in Iran raising concerns over oil supply stability.

11 jun 2026, 23:46 UTC

Intuitive Surgical Inc. shares are higher in after-market trading, advancing modestly since Thursday's close despite remaining below the 20-day moving average.

11 jun 2026, 23:46 UTC

Oil (Brent) is trading roughly flat with no specific news identified. It remains 7.63% below its 20-day moving average, indicating weak performance.

11 jun 2026, 23:46 UTC

ETF Constituents
Correlated Moves

The Vanguard FTSE Developed Markets ETF is trading higher in after-market hours, buoyed by the European Central Bank's interest rate hike and strong performances from SAP and BP.

11 jun 2026, 23:42 UTC

Housing Starts Data Release on June 16, 2026 Expected at 1.44 Million Amid Mixed Economic Sentiment and Inflation Concerns

11 jun 2026, 23:42 UTC

U.S. Import Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of June 16 Release

11 jun 2026, 23:42 UTC

U.S. Export Prices Expected to Rise 1% MoM Amid Mixed Economic Sentiment and Geopolitical Tensions Ahead of June 16 Release

11 jun 2026, 23:42 UTC

Market Awaits May Housing Starts Data Amid Economic Uncertainties and Rising Costs.

11 jun 2026, 23:42 UTC

U.S. Building Permits Expected to Rise Slightly to 1.41 Million Amid Cautious Optimism Ahead of June Release

11 jun 2026, 23:42 UTC

Macro News
ETF Constituents

Investor sentiment towards the Consumer Staples Select Sector SPDR Fund improves in after-market trading, buoyed by macro developments and strong performances from key holdings.

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

49.89% repunte

Estimación a 12 Meses

Media 21 USD  49.89%

Máximo 30 USD

Mínimo 12 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

8

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat